Skip to main content
SpringerLink
Log in

Evidence-Based Cancer Prevention Research: A Multidisciplinary Perspective on Cancer Prevention Trials

  • Chapter
Oncology

  • 239 Accesses

Abstract

More than 1 million Americans were expected to be diagnosed with cancer in 2004. This fact is especially tragic given that many cancers are preventable. The ongoing challenge to the medical, scientific, and public health communities is to formulate evidencebased decisions and implement effective and safe interventions for cancer prevention.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Peto R, Doll R, Buckley JD, Sporn MB. Can dietary beta-carotene materially reduce human cancer rates? Nature (Lond) 1981;290(5803):201–208.

    Article  CAS  Google Scholar 

  2. Peto R. Cancer, cholesterol, carotene, and tocopherol. Lancet 1981;2(8237):97–98.

    Article  PubMed  CAS  Google Scholar 

  3. Hursting SD, Slaga TJ, Fischer SM, DiGiovanni J, Phang JM. Mechanism-based cancer prevention approaches: targets, examples, and the use of transgenic mice. J Natl Cancer Inst 1999;91(3):215–225.

    Article  PubMed  CAS  Google Scholar 

  4. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61(5):759–767.

    Article  PubMed  CAS  Google Scholar 

  5. Stanley LA. Molecular aspects of chemical carcinogenesis: the roles of oncogenes and tumour suppressor genes. Toxicology 1995;96(3):173–194.

    Article  PubMed  CAS  Google Scholar 

  6. Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 1976;36(7 pt 2):2699–2702.

    PubMed  CAS  Google Scholar 

  7. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976;35(6):1332–1338.

    PubMed  CAS  Google Scholar 

  8. Mathews-Roth MM. Beta-carotene therapy for erythropoietic protoporphyria and other photosensitivity diseases. Biochimie (Paris) 1986;68(6):875–884.

    CAS  Google Scholar 

  9. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994;330(15):1029–1035.

    Google Scholar 

  10. Albanes D, Heinonen OP, Taylor PR, et al. Alpha-tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 1996;88(21):1560–1570.

    Article  PubMed  CAS  Google Scholar 

  11. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334(18):1150–1155.

    Article  PubMed  CAS  Google Scholar 

  12. Koo LC. Diet and lung cancer 20+ years later: more questions than answers? Int J Cancer 1997;10(suppl):22–29.

    Article  PubMed  Google Scholar 

  13. Wang XD, Liu C, Bronson RT, et al. Retinoid signaling and activator protein-1 expression in ferrets given beta-carotene supplements and exposed to tobacco smoke. J Natl Cancer Inst 1999;91(1):60–66.

    Article  PubMed  CAS  Google Scholar 

  14. Liu C, Lian F, Smith DE, et al. Lycopene supplementation inhibits lung squamous metaplasia and induces apoptosis via up-regulating insulin-like growth factor-binding protein 3 in cigarette smoke-exposed ferrets. Cancer Res 2003;63(12):3138–3144.

    PubMed  CAS  Google Scholar 

  15. Martin KR, Saulnier MJ, Kari FW, et al. Timing of supplementation with the antioxidant N-acetyl-L-cysteine reduces tumor multiplicity in novel, cancer-prone p53 haploinsufficient Tg.AC (v-Ha-ras) transgenic mice but has no impact on malignant progression. Nutr Cancer 2002;43(1):59–66.

    Article  PubMed  CAS  Google Scholar 

  16. Brown ED, Micozzi MS, Craft NE, et al. Plasma carotenoids in normal men after a single ingestion of vegetables or purified beta-carotene. Am J Clin Nutr 1989;49(6):1258–1265.

    PubMed  CAS  Google Scholar 

  17. Dimitrov NV, Meyer C, Ullrey DE, et al. Bioavailability of beta-carotene in humans. Am J Clin Nutr 1988;48(2):298–304.

    PubMed  CAS  Google Scholar 

  18. Micozzi MS, Brown ED, Taylor PR, Wolfe E. Carotenodermia in men with elevated carotenoid intake from foods and beta-carotene supplements. Am J Clin Nutr 1988;48(4):1061–1064.

    PubMed  CAS  Google Scholar 

  19. Mathews-Roth MM. Plasma concentrations of carotenoids after large doses of beta-carotene. Am J Clin Nutr 1990;52(3):500–501.

    PubMed  CAS  Google Scholar 

  20. Albanes D, Virtamo J, Taylor PR, et al. Effects of supplemental beta-carotene, cigarette smoking, and alcohol consumption on serum carotenoids in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Am J Clin Nutr 1997;66(2):366–372.

    PubMed  CAS  Google Scholar 

  21. Locke FB, King H. Cancer mortality risk among Japanese in the United States. J Natl Cancer Inst 1980;65(5):1149–1156.

    PubMed  CAS  Google Scholar 

  22. Reddy BS. Dietary fat and cancer: specific action or caloric effect. J Nutr 1986;116(6):1132–1135.

    PubMed  CAS  Google Scholar 

  23. Reddy BS. Dietary fiber and colon cancer: animal model studies. Prev Med 1987;16(4):559–565.

    Article  PubMed  CAS  Google Scholar 

  24. Reddy BS. Prevention of colon carcinogenesis by components of dietary fiber. Anticancer Res 1999;19(5A):3681–3683.

    PubMed  CAS  Google Scholar 

  25. Schatzkin A, Lanza E, Corle D, et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N Engl J Med 2000;342(16):1149–1155.

    Article  PubMed  CAS  Google Scholar 

  26. Alberts DS, Martinez ME, Roe DJ, et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians’ Network. N Engl J Med 2000;342(16):1156–1162.

    Article  PubMed  CAS  Google Scholar 

  27. MacLennan R, Macrae F, Bain C, et al. Randomized trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas. The Australian Polyp Prevention Project. J Natl Cancer Inst 1995;87(23):1760–1766.

    Article  PubMed  CAS  Google Scholar 

  28. Bonithon-Kopp C, Kronborg O, et al. Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organisation Study Group. Lancet 2000;356(9238):1300–1306.

    Article  PubMed  CAS  Google Scholar 

  29. McKeown-Eyssen GE, Bright-See E, Bruce WR, et al. A randomized trial of a low fat high fibre diet in the recurrence of colorectal polyps. Toronto Polyp Prevention Group. J Clin Epidemiol 1994;47(5):525–536.

    Article  PubMed  CAS  Google Scholar 

  30. Lanza E, Schatzkin A, Daston C, et al. Implementation of a 4-y, high-fiber, high-fruit-and-vegetable, low-fat dietary intervention: results of dietary changes in the Polyp Prevention Trial. Am J Clin Nutr 2001;74(3):387–401.

    PubMed  CAS  Google Scholar 

  31. Willett WC. Nutritional Epidemiology. New York: Oxford University Press, 1999.

    Google Scholar 

  32. Mangels AR, Holden JM, Beecher GR, et al. Carotenoid content of fruits and vegetables: an evaluation of analytic data. J Am Diet Assoc 1993;93(3):284–296.

    Article  PubMed  CAS  Google Scholar 

  33. Michels KB, Edward G, Joshipura KJ, et al. Prospective study of fruit and vegetable consumption and incidence of colon and rectal cancers. J Natl Cancer Inst 2000;92(21):1740–1752.

    Article  PubMed  CAS  Google Scholar 

  34. Fuchs CS, Giovannucci EL, Colditz GA, et al. Dietary fiber and the risk of colorectal cancer and adenoma in women. N Engl J Med 1999;340(3):169–176.

    Article  PubMed  CAS  Google Scholar 

  35. Peters U, Sinha R, Chatterjee N, et al. Dietary fibre and colorectal adenoma in a colorectal cancer early detection programme. Lancet 2003;361(9368):1491–1495.

    Article  PubMed  Google Scholar 

  36. Bingham SA, Day NE, Luben R, et al. Dietary fibre in food and regulating insulin-like growth factor-binding protein 3 in cigarette smoke-exposed ferrets. Cancer Res 2003;63(12):3138–3144.

    Google Scholar 

  37. Kim ES, Hong WK, Khuri FR. Chemoprevention of aerodigestive tract cancers. Annu Rev Med 2002;53:223–243.

    Article  PubMed  CAS  Google Scholar 

  38. Hong WK, Endicott J, Itri LM, et al. 13-cis-Retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986;315(24):1501–1505.

    Article  PubMed  CAS  Google Scholar 

  39. Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis. N Engl J Med 1993;328(1):15–20.

    Article  PubMed  CAS  Google Scholar 

  40. Papadimitrakopoulou VA, Hong WK, Lee JS, et al. Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: long-term follow-up. J Natl Cancer Inst 1997;89(3):257–258.

    Article  PubMed  CAS  Google Scholar 

  41. Tsiklakis K, Papadakou A, Angelopoulos AP. The therapeutic effect of an aromatic retinoid (RO-109359) on hamster buccal pouch carcinomas. Oral Surg Oral Med Oral Pathol 1987;64(3):327–332.

    Article  PubMed  CAS  Google Scholar 

  42. Alam BS, Alam SQ. The effect of different levels of dietary beta-carotene on DMBA-induced salivary gland tumors. Nutr Cancer 1987;9(2–3):93–101.

    PubMed  CAS  Google Scholar 

  43. Stich HF, Tsang SS. Promoting activity of betel quid ingredients and their inhibition by retinol. Cancer Lett 1989;45(1):71–77.

    Article  PubMed  CAS  Google Scholar 

  44. Lee JJ, Hong WK, Hittelman WN, et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 2000;6(5):1702–1710.

    PubMed  CAS  Google Scholar 

  45. Sun SY, Yue P, Wu GS, et al. Implication of p53 in growth arrest and apoptosis induced by the synthetic retinoid CD437 in human lung cancer cells. Cancer Res 1999;59(12):2829–2833.

    PubMed  CAS  Google Scholar 

  46. Sun SY, Yue P, Kelloff GJ, et al. Identification of retinamides that are more potent than N-(4-hydroxyphenyl)retinamide in inhibiting growth and inducing apoptosis of human head and neck and lung cancer cells. Cancer Epidemiol Biomarkers Prev 2001;10(6):595–601.

    PubMed  CAS  Google Scholar 

  47. Lippman SM, Shin DM, Lee JJ, et al. p53 and retinoid chemoprevention of oral carcinogenesis. Cancer Res 1995;55(1):16–9.

    PubMed  CAS  Google Scholar 

  48. Papadimitrakopoulou VA, Clayman GL, Shin DM, et al. Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg 1999;125(10):1083–1089.

    PubMed  CAS  Google Scholar 

  49. Mao L, El-Naggar AK, Papadimitrakopoulou V, et al. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst 1998;90(20):1545–1551.

    Article  PubMed  CAS  Google Scholar 

  50. Shin DM, Mao L, Papadimitrakopoulou VM, et al. Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression. J Natl Cancer Inst 2000;92(1):69–73.

    Article  PubMed  CAS  Google Scholar 

  51. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323(12):795–801.

    Article  PubMed  CAS  Google Scholar 

  52. Benner SE, Pajak TF, Lippman SM, et al. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J Natl Cancer Inst 1994;86(2):140–141.

    Article  PubMed  CAS  Google Scholar 

  53. Khuri FR, Kim ES, Lee JJ, et al. The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev 2001;10(8):823–829.

    PubMed  CAS  Google Scholar 

  54. Spitz MR, Fueger JJ, Beddingfield NA, et al. Chromosome sensitivity to bleomycin-induced mutagenesis, an independent risk factor for upper aerodigestive tract cancers. Cancer Res 1989;49(16):4626–4628.

    PubMed  CAS  Google Scholar 

  55. Wu X, Gu J, Hong WK, et al. Benzo[a]pyrene diol epoxide and bleomycin sensitivity and susceptibility to cancer of upper aerodigestive tract. J Natl Cancer Inst 1998;90(18):1393–1399.

    Article  PubMed  CAS  Google Scholar 

  56. Spitz MR, Hoque A, Trizna Z, et al. Mutagen sensitivity as a risk factor for second malignant tumors following malignancies of the upper aerodigestive tract. J Natl Cancer Inst 1994;86(22):1681–1684.

    Article  PubMed  CAS  Google Scholar 

  57. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003;53(1):5–26.

    PubMed  Google Scholar 

  58. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003;95(17):1276–1299.

    PubMed  Google Scholar 

  59. Tamoxifen for early breast cancer: an overview of the randomized trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998;351(9114):1451–1467.

    Google Scholar 

  60. Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet 1985;2(8449):282.

    Article  PubMed  CAS  Google Scholar 

  61. Fisher B, Jeong JH, Dignam J, et al. Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. J Natl Cancer Inst Monogr 2001(30):62–66.

    PubMed  Google Scholar 

  62. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists’ Collaborative Group. N Engl J Med 1988;319(26):1681–1692.

    Google Scholar 

  63. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet 1983;1(8319):257–261.

    Google Scholar 

  64. Dunn BK, Ford LG. From adjuvant therapy to breast cancer prevention: BCPT and STAR. Breast J 2001;7(3):144–157.

    Article  PubMed  CAS  Google Scholar 

  65. Jordan VC, Fritz NF, Langan-Fahey S, et al. Alteration of endocrine parameters in premenopausal women with breast cancer during long-term adjuvant therapy with tamoxifen as the single agent. J Natl Cancer Inst 1991;83(20):1488–1491.

    Article  PubMed  CAS  Google Scholar 

  66. Veronesi U, Maisonneuve P, Rotmensz N, et al. Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003;95(2):160–165.

    PubMed  CAS  Google Scholar 

  67. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomized prevention trial. Lancet 2002;360(9336):817–824.

    Article  PubMed  CAS  Google Scholar 

  68. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998;352(9122):93–97.

    Article  PubMed  CAS  Google Scholar 

  69. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352(9122):98–101.

    Article  PubMed  CAS  Google Scholar 

  70. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 2001;286(18):2251–2256.

    Article  PubMed  CAS  Google Scholar 

  71. Couzin J. Choices—and uncertainties—for women with BRCA mutations. Science 2003;302(5645):592.

    Article  PubMed  CAS  Google Scholar 

  72. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350(11):1081–1092.

    Article  PubMed  CAS  Google Scholar 

  73. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19(10):2596–2606.

    PubMed  CAS  Google Scholar 

  74. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349(19):1793–1802.

    Article  PubMed  CAS  Google Scholar 

  75. Long BJ, Jelovac D, Handratta V, et al. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J Natl Cancer Inst 2004;96(6):456–465.

    PubMed  CAS  Google Scholar 

  76. Brodie A. Aromatase inhibitors and the application to the treatment of breast cancer. In: Pasqualini J (ed). Breast Cancer: Prognosis, Treatment and Prevention. New York: Dekker, 2002:251–270.

    Google Scholar 

  77. Mouridsen H, Gershanovich M. The role of aromatase inhibitors in the treatment of metastatic breast cancer. Semin Oncol 2003;30(4 suppl 14):33–45.

    Article  PubMed  CAS  Google Scholar 

  78. Dickler MN, Norton L. The MORE trial: multiple outcomes for raloxifene evaluation—breast cancer as a secondary end point: implications for prevention. Ann NY Acad Sci 2001;949:134–142.

    Article  PubMed  CAS  Google Scholar 

  79. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349(3):215–224.

    Article  PubMed  CAS  Google Scholar 

  80. Kadohama N, Karr JP, Murphy GP, Sandberg AA. Selective inhibition of prostatic tumor 5 alpha-reductase by a 4-methyl-4-azasteroid. Cancer Res 1984;44(11):4947–4954.

    PubMed  CAS  Google Scholar 

  81. Petrow V, Padilla GM, Mukherji S, Marts SA. Endocrine dependence of prostatic cancer upon dihydrotestosterone and not upon testosterone. J Pharm Pharmacol 1984;36(5):352–353.

    PubMed  CAS  Google Scholar 

  82. Huynh H. Induction of apoptosis in rat ventral prostate by finasteride is associated with alteration in MAP kinase pathways and Bcl-2 related family of proteins. Int J Oncol 2002;20(6):1297–1303.

    PubMed  Google Scholar 

  83. Doggrell SA. Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia. Expert Opin Pharmacother 2004;5(5):1209–1211.

    Article  PubMed  CAS  Google Scholar 

  84. Punglia RS, D’Amico AV, Catalona WJ, et al. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003;349(4):335–342.

    Article  PubMed  Google Scholar 

  85. Scardino PT. The prevention of prostate cancer—the dilemma continues. N Engl J Med 2003;349(3):297–299.

    Article  PubMed  Google Scholar 

  86. Barqawi A, Thompson IM, Crawford ED. Prostate cancer chemoprevention: an overview of United States trials. J Urol 2004;171(2 pt 2):S5–S8; discussion S9.

    Article  PubMed  Google Scholar 

  87. Holt PR. Dairy foods and prevention of colon cancer: human studies. J Am Coll Nutr 1999;18(5 suppl):379S–391S.

    PubMed  CAS  Google Scholar 

  88. Sorenson AW, Slattery ML, Ford MH. Calcium and colon cancer: a review. Nutr Cancer 1988;11(3):135–145.

    Article  PubMed  CAS  Google Scholar 

  89. Lipkin M. Early development of cancer chemoprevention clinical trials: studies of dietary calcium as a chemopreventive agent for human subjects. Eur J Cancer Prev 2002;11(suppl 2):S65–S670.

    PubMed  Google Scholar 

  90. Hofstad B, Almendingen K, Vatn M, et al. Growth and recurrence of colorectal polyps: a double-blind 3-year intervention with calcium and antioxidants. Digestion 1998;59(2):148–156.

    Article  PubMed  CAS  Google Scholar 

  91. Baron JA, Beach M, Mandel JS, et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N Engl J Med 1999;340(2):101–107.

    Article  PubMed  CAS  Google Scholar 

  92. Design of the Women’s Health Initiative clinical trial and observational study. The Women’s Health Initiative Study Group. Control Clin Trials 1998;19(1):61–109.

    Google Scholar 

  93. FitzGerald GA. Coxibs and cardiovascular disease. N Engl J Med 351:1709–1711.

    Google Scholar 

  94. Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004;363(9423):1751–1756.

    Article  PubMed  CAS  Google Scholar 

  95. Pollard M, Luckert PH. Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors. Cancer Treat Rep 1980;64(12):1323–1327.

    PubMed  CAS  Google Scholar 

  96. Hawk ET, Viner JL, Umar A, et al. Cancer and the cyclooxygenase enzyme: implications for the treatment and prevention. Am J Cancer 2003;2(1):27–55.

    Article  CAS  Google Scholar 

  97. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87(5):803–809.

    Article  PubMed  CAS  Google Scholar 

  98. Paganini-Hill A, Hsu G, Ross RK, Henderson BE. Aspirin use and incidence of large-bowel cancer in a California retirement community. J Natl Cancer Inst 1991;83(16):1182–1183.

    Article  PubMed  CAS  Google Scholar 

  99. Sturmer T, Glynn RJ, Lee IM, et al. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians’ Health Study. Ann Intern Med 1998;128(9):713–720.

    PubMed  CAS  Google Scholar 

  100. Garcia Rodriguez LA, Huerta-Alvarez C. Reduced incidence of colorectal adenoma among long-term users of nonsteroidal anti-inflammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology 2000;11(4):376–381.

    Article  PubMed  CAS  Google Scholar 

  101. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348(10):891–899.

    Article  PubMed  CAS  Google Scholar 

  102. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348(10):883–890.

    Article  PubMed  CAS  Google Scholar 

  103. Bosetti C, Talamini R, Franceschi S, et al. Aspirin use and cancers of the upper aerodigestive tract. Br J Cancer 2003;88(5):672–674.

    Article  PubMed  CAS  Google Scholar 

  104. Iyngkaran N, Yadav M, Boey CG, Lam KL. Severity and extent of upper small bowel mucosal damage in cow’s milk protein-sensitive enteropathy. J Pediatr Gastroenterol Nutr 1988;7(5):667–674.

    Article  PubMed  CAS  Google Scholar 

  105. Helzlsouer KJ. Early detection and prevention of breast cancer. In: Greenwald P, Kramer BS, Weed DL (eds). Cancer Prevention and Control. New York: Dekker, 1995:509–535.

    Google Scholar 

  106. Bondy ML, Newman LA. Breast cancer risk assessment models: applicability to African-American women. Cancer (Phila) 2003;97(suppl 1):230–235.

    Article  PubMed  Google Scholar 

  107. Tsao AS, Kim ES, Hong WK. Chemoprevention of cancer. CA Cancer J Clin 2004;54(3):150–180.

    Article  PubMed  Google Scholar 

  108. DeCosse JJ, Miller HH, Lesser ML. Effect of wheat fiber and vitamins C and E on rectal polyps in patients with familial adenomatous polyposis. J Natl Cancer Inst 1989;81(17):1290–1297.

    Article  PubMed  CAS  Google Scholar 

  109. Martinez ME, Reid ME, Guillen-Rodriguez J, et al. Design and baseline characteristics of study participants in the Wheat Bran Fiber trial. Cancer Epidemiol Biomarkers Prev 1998;7(9):813–816.

    PubMed  CAS  Google Scholar 

  110. Earnest DL, Sampliner RE, Roe DJ, et al. Progress report: the Arizona phase III study of the effect of wheat bran fiber on recurrence of adenomatous colon polyps. Am J Med 1999;106(1A):43S–45S.

    Article  PubMed  CAS  Google Scholar 

  111. Faivre J, Couillault C, Kronborg O, et al. Chemoprevention of metachronous adenomas of the large bowel: design and interim results of a randomized trial of calcium and fibre. ECP Colon Group. Eur J Cancer Prev 1997;6(2):132–138.

    PubMed  CAS  Google Scholar 

  112. Matsuhashi N, Nakajima A, Fukushima Y, et al. Effects of sulindac on sporadic colorectal adenomatous polyps. Gut 1997;40(3):344–349.

    PubMed  CAS  Google Scholar 

  113. Ladenheim J, Garcia G, Titzer D, et al. Effect of sulindac on sporadic colonic polyps. Gastroenterology 1995;108(4):1083–1087.

    Article  PubMed  CAS  Google Scholar 

  114. Hixson LJ, Earnest DL, Fennerty MB, Sampliner RE. NSAID effect on sporadic colon polyps. Am J Gastroenterol 1993;88(10):1652–1656.

    PubMed  CAS  Google Scholar 

  115. Carbone PP, Douglas JA, Larson PO, et al. Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine. Cancer Epidemiol Biomarkers Prev 1998;7(10):907–912.

    PubMed  CAS  Google Scholar 

  116. Calaluce R, Earnest DL, Heddens D, et al. Effects of piroxicam on prostaglandin E2 levels in rectal mucosa of adenomatous polyp patients: a randomized phase IIb trial. Cancer Epidemiol Biomarkers Prev 2000;9(12):1287–1292.

    PubMed  CAS  Google Scholar 

  117. Chow HH, Earnest DL, Clark D, et al. Effect of subacute ibuprofen dosing on rectal mucosal prostaglandin E2 levels in healthy subjects with a history of resected polyps. Cancer Epidemiol Biomarkers Prev 2000;9(4):351–356.

    PubMed  CAS  Google Scholar 

  118. Barnes CJ, Hamby-Mason RL, Hardman WE, et al. Effect of aspirin on prostaglandin E2 formation and transforming growth factor alpha expression in human rectal mucosa from individuals with a history of adenomatous polyps of the colon. Cancer Epidemiol Biomarkers Prev 1999;8(4 pt 1):311–315.

    PubMed  CAS  Google Scholar 

  119. Ruffin MT, Krishnan K, Rock CL, et al. Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. J Natl Cancer Inst 1997;89(15):1152–1160.

    Article  PubMed  CAS  Google Scholar 

  120. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993;85(15):1220–1224.

    Article  PubMed  CAS  Google Scholar 

  121. Baron JA, Cole BF, Mott LA, et al. Aspirin chemoprevention of colorectal adenomas. Proc AACR 2002;43:669.

    Google Scholar 

  122. Benamouzig R, Deyra J, Martin A, et al. Efficacy of lysin acetylsalicylate to prevent colorectal adenomas: one year results of the APACC Randomized Trial. Gastroenterology 2002;122:A70 (abstract).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Office of Preventive Oncology, National Cancer Institute, Bethesda, MD, USA

    Stephen D. Hursting PhD, MPH (Deputy Director)

  2. Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA

    Michele R. Forman PhD (Senior Investigator), Nomeli P. Nunez PhD, MPH (Cancer Prevention Fellow) & J. Carl Barrett PhD (Director)

  3. Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Rockville, MD, USA

    Asad Umar DVM, PhD (Program Director)

Authors
  1. Stephen D. Hursting PhD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michele R. Forman PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Asad Umar DVM, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nomeli P. Nunez PhD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Carl Barrett PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Division of Surgery Oncology, Department of Surgery, University of Michigan, Ann Arbor, MI, USA

    Alfred E. Chang MD (Hugh Cabot Professor of Surgery and Chief) (Hugh Cabot Professor of Surgery and Chief)

  2. Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA

    Daniel F. Hayes MD (Clinical Director) (Clinical Director)

  3. Department of Cardiothoracic Surgery, New York University School of Medicine and Comprehensive Cancer Center, New York, NY, USA

    Harvey I. Pass MD (Professor and Chief of Thoracic Surgery and Head) (Professor and Chief of Thoracic Surgery and Head)

  4. Thoracic Oncology, New York University School of Medicine and Comprehensive Cancer Center, New York, NY, USA

    Harvey I. Pass MD (Professor and Chief of Thoracic Surgery and Head) (Professor and Chief of Thoracic Surgery and Head)

  5. Department of Medicine, Harvard Medical School, USA

    Richard M. Stone MD (Associate Professor and Clinical Director) (Associate Professor and Clinical Director)

  6. Adult Leukemia Program, Dana-Farber Cancer Institute, Boston, MA, USA

    Richard M. Stone MD (Associate Professor and Clinical Director) (Associate Professor and Clinical Director)

  7. Division of Cancer Prevention and Control Research, Jonsson Comprehensive Cancer Center at UCLA, USA

    Patricia A. Ganz MD (American Cancer Society Clinical Research Professor, Director and Professor) (American Cancer Society Clinical Research Professor, Director and Professor)

  8. Schools of Public Health and Medicine, University of California, Los Angeles, Los Angeles, CA, USA

    Patricia A. Ganz MD (American Cancer Society Clinical Research Professor, Director and Professor) (American Cancer Society Clinical Research Professor, Director and Professor)

  9. Department of Radiation Oncology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA

    Timothy J. Kinsella MD (Vincent K. Smith Professor and Chairman) (Vincent K. Smith Professor and Chairman)

  10. Department of Medicine, University of Wisconsin Comprehensive Cancer Center, Madison, WI, USA

    Joan H. Schiller MD (Melanie Heald Professor of Medical Oncology) (Melanie Heald Professor of Medical Oncology)

  11. Health Media Research Laboratory, Department of Health Behavior and Health Education, University of Michigan School of Public Health, USA

    Victor J. Strecher PhD, MPH (Professor and Director and Associate Director) (Professor and Director and Associate Director)

  12. Cancer Prevention and Control, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA

    Victor J. Strecher PhD, MPH (Professor and Director and Associate Director) (Professor and Director and Associate Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Hursting, S.D., Forman, M.R., Umar, A., Nunez, N.P., Barrett, J.C. (2006). Evidence-Based Cancer Prevention Research: A Multidisciplinary Perspective on Cancer Prevention Trials. In: Chang, A.E., et al. Oncology. Springer, New York, NY. https://doi.org/10.1007/0-387-31056-8_23

Download citation

  • DOI: https://doi.org/10.1007/0-387-31056-8_23

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-24291-0

  • Online ISBN: 978-0-387-31056-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation